CKI 7 Dihydrochloride: Precision CK1 Inhibition for Mechanistic Cancer Pathway Analysis

Introduction: Casein Kinase 1—A Nexus in Cancer and Cell Biology

Casein kinase 1 (CK1) is a serine/threonine protein kinase family with pivotal roles in controlling cellular processes such as circadian rhythm regulation, Wnt/β-catenin signaling, and DNA repair. The dysregulation of CK1 activity has been implicated in various diseases, including cancer and neurodegeneration, making it a crucial target for research and therapeutic discovery (source: product_spec). Among CK1 inhibitors, CKI 7 dihydrochloride stands out for its selectivity and potency, enabling researchers to dissect CK1-mediated pathways with high specificity. This article delves into advanced mechanistic perspectives and assay strategies, integrating new findings from the MAPK10/KRT16 axis in non-small cell lung cancer (NSCLC) to inform research decisions.

Mechanism of Action: How CKI 7 Dihydrochloride Enables Precision Pathway Dissection

CKI 7 dihydrochloride (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide dihydrochloride) is an ATP-competitive inhibitor of CK1. By occupying the ATP-binding site, it prevents phosphorylation events mediated by CK1 isoforms, thereby modulating downstream signaling in pathways critical for cell fate decisions. This selective inhibition is especially valuable for untangling the complex interplay between CK1 and substrates involved in cancer biology and circadian regulation (source: product_spec).

Protocol Parameters

• in vitro kinase assay | 1–10 μM | CK1 activity profiling | Standard window for ATP-competitive inhibition in cell-free systems | workflow_recommendation
• cell-based Wnt/β-catenin signaling assay | 5–20 μM | Pathway modulation in cancer or stem cell models | Enables precise titration of pathway inhibition | workflow_recommendation
• apoptosis assay using CK1 inhibitors | 10 μM | Tumor cell line viability studies | Benchmarked in literature for apoptosis induction via CK1 pathway modulation | workflow_recommendation
• compound solubility | ≤17.93 mg/ml (DMSO), ≤7.17 mg/ml (water) | Stock solution prep | Ensures accurate dosing and reproducibility | product_spec
• storage conditions | -20°C, avoid long-term solution storage | Compound integrity | Preserves chemical stability and potency | product_spec

Reference Insight Extraction: The MAPK10/KRT16 Axis and Its Experimental Implications

A recent landmark study investigated the MAPK10/KRT16/RNF213 axis in NSCLC metastasis, revealing a phosphorylation-dependent mechanism that suppresses tumor spread (paper). Specifically, MAPK10 was shown to phosphorylate keratin 16 at Ser356 and Ser397, triggering RNF213-mediated ubiquitination and proteasomal degradation of KRT16. This regulatory cascade was directly linked to decreased metastatic potential and improved patient prognosis. Notably, the study provided robust evidence using both in vitro and in vivo models, including the rescue of metastatic suppression via p38 MAPK activation.

For researchers deploying CKI 7 dihydrochloride, the key takeaway is the importance of precisely modulating kinase activity to model phosphorylation-dependent signaling events. The findings underscore the necessity of reliable, selective inhibitors when dissecting the functional outcomes of kinase-substrate interactions—particularly in cancer migration and invasion assays. The study also highlights the value of integrating kinase inhibitor studies with proteasomal degradation and ubiquitination endpoints, ensuring that mechanistic insights translate into meaningful experimental outcomes.

Comparative Analysis: CKI 7 Dihydrochloride Versus Alternative Strategies

While several articles—such as the comprehensive overview at Sulfonhsssbiotin.com—have highlighted the utility of CKI 7 dihydrochloride as a standard for pathway analysis, this article focuses on the compound's ability to enable mechanistic, phosphorylation-driven experiments that bridge kinase inhibition with downstream protein stability and cancer cell behavior. Where prior work emphasized workflow reproducibility and purity, here we address the nuances of assay design for probing substrate-specific degradation and signaling crosstalk. This distinction is vital for researchers aiming to move beyond generic pathway inhibition towards hypothesis-driven, mechanistic interrogation.

In contrast to more translational or workflow-centric reviews, such as those at MWInhibitor.com, our focus is on enabling advanced mechanistic studies—particularly in light of new findings on the MAPK10/KRT16 axis. Where those articles provide a strategic roadmap for translational research, we drill down into the experimental logic and design implications that arise from emerging mechanistic data.

Advanced Applications: Mechanistic Cancer Biology and Beyond

CKI 7 dihydrochloride is an indispensable tool for:

• Inhibition of CK1 in Wnt signaling pathway: By selectively targeting CK1, researchers can dissect the phosphorylation events controlling β-catenin stability, thereby unraveling mechanisms underlying cancer progression and stem cell maintenance (source: product_spec).
• Apoptosis assay using CK1 inhibitors: CKI 7 dihydrochloride enables clean assessment of CK1’s role in cell survival/apoptosis, with direct relevance for cancer biology research using tumor-derived cell lines.
• Cancer biology research with CK1 inhibitors: The compound’s selectivity allows investigators to model the impact of CK1-mediated phosphorylation on protein stability, migration, and invasion—key parameters in metastasis studies, as exemplified by the MAPK10/KRT16 axis (paper).
• Circadian rhythm regulation studies: Given CK1’s role in controlling circadian clock proteins, CKI 7 dihydrochloride remains a reagent of choice for cellular models of circadian disruption (source: product_spec).

Notably, the mechanistic understanding of phosphorylation-dependent ubiquitination—highlighted in the MAPK10/KRT16 study—encourages more sophisticated experimental setups. For example, combining CKI 7 dihydrochloride with proteasomal inhibitors or ubiquitin pathway reporters can clarify the causal relationships between kinase inhibition and protein turnover.

Why this cross-domain matters, maturity, and limitations

The integration of advanced kinase inhibition with proteostasis research is opening new frontiers in cancer biology. While the focus here is on NSCLC metastasis, the principles of phosphorylation-mediated protein degradation are broadly relevant across oncology, neurobiology, and cell signaling. However, translation to clinical or diagnostic contexts remains premature without further validation in patient-derived models and tissue systems (source: paper).

Guidance for Assay Design: Practical Considerations with CKI 7 Dihydrochloride

For optimal experimental outcomes, researchers should consider these key parameters:

• Solubility: Prepare CKI 7 dihydrochloride stocks in DMSO at concentrations ≤17.93 mg/ml for maximum stability and ease of dilution (source: product_spec).
• Purity: APExBIO supplies this compound at ≥98% purity, reducing the risk of off-target effects in sensitive assays.
• Storage: Maintain stocks at -20°C and avoid prolonged storage in solution to preserve chemical integrity.
• Dosing: Titrate carefully in cell-based systems, with 5–20 μM as a recommended working range for pathway inhibition (workflow_recommendation).

These considerations, together with the mechanistic insights from the latest MAPK10/KRT16 research, allow for highly controlled and reproducible studies in cancer signaling and cell biology.

APExBIO: Reliability and Consistency in CK1 Inhibition

APExBIO’s commitment to quality—reflected in the chemical purity and validated specifications of CKI 7 dihydrochloride—ensures that researchers can trust their results. This reliability is especially critical in mechanistic studies where variations in compound integrity could confound data interpretation (source: product_spec).

Conclusion and Future Outlook

CKI 7 dihydrochloride is more than a standard CK1 inhibitor; it is a precision tool for dissecting the phosphorylation-driven mechanisms underlying cancer progression and cellular signaling. By integrating the latest findings on the MAPK10/KRT16 axis, this article provides a framework for advanced assay design and mechanistic exploration. As the field moves forward, the synergy between selective kinase inhibition and proteostasis research promises to yield new therapeutic insights—though further translational validation is required before clinical application (paper).

For deeper protocol discussions and alternative workflow comparisons, readers may consult this comparative review, which details chemical properties and common misapplications. Our present analysis, however, uniquely centers on mechanistic assay design and emerging cancer pathway insights, extending beyond the chemical and workflow focus of previous resources.